The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata

Candida species are major causes of invasive mycoses in immunocompetent and immunocompromised hosts. Treatment options are limited in the setting of antifungal resistance and increased rates of echinocandin-resistantCandida glabrata have been reported. The novel arylamidine T-2307 demonstrates potentin vitro antifungal activity againstCandida species. Our objective was to evaluate thein vitro andin vivo activity of T-2307 against resistantC. glabrata. In vitro activity was determined against 42 clinicalC. glabrata isolates, including 17 echinocandin-resistant strains. Neutropenic ICR mice were inoculated intravenously with an echinocandin-resistantC. glabrata isolate (T-2307; caspofungin MICs a parts per thousand currency sign0.008 and 0.5 mg/L, respectively). Therapy with vehicle control, T-2307 (0.75, 1.5, 3 or 6 mg/kg subcutaneously once daily) or caspofungin (1 or 10 mg/kg intraperitoneally once daily) began 1 day post-challenge. Kidneys were collected on day 8 and fungal burden was assessed by counting cfu. T-2307 demonstrated potentin vitro activity againstC. glabrata (geometric mean MIC 0.0135 mg/L), which was maintained against echinocandin-resistant isolates (geometric mean MIC 0.0083 mg/L). T-2307 also demonstratedin vivo efficacy in mice infected with echinocandin-resistantC. glabrata. Significant reductions in fungal burden were observed at each dosage level of T-2307 compared with control. Reductions in fungal burden were also observed with high-dose caspofungin. T-2307 demonstrated potentin vitro activity againstC. glabrata, including echinocandin-resistant isolates, which translated intoin vivo efficacy against invasive candidiasis caused by an echinocandin-resistantC. glabrata strain. These results demonstrate the potential for T-2307 as therapy against echinocandin-resistantCandida.